Premium
Therapy‐related acute myeloid leukemia after single‐agent treatment with fludarabine for chronic lymphocytic leukemia
Author(s) -
Lam Clarence C.K.,
Ma Edmond S.K.,
Kwong YokLam
Publication year - 2005
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20340
Subject(s) - fludarabine , medicine , chronic lymphocytic leukemia , myeloid leukemia , purine analogue , leukemia , antimetabolite , pancytopenia , oncology , minimal residual disease , myeloid , immunology , chemotherapy , bone marrow , cyclophosphamide , purine , biology , biochemistry , enzyme
A 70‐year‐old man with B‐cell chronic lymphocytic leukemia (CLL) received single‐agent treatment with the purine analogue fludarabine, which led to complete remission. After 8 years, he presented with pancytopenia. Marrow examination showed acute myeloid leukemia (AML) with trilineage myelodysplasia (MDS). Cytogenetic analysis showed an unbalanced der(1;7)(p10;q10) that resulted effectively in deletion 7q; confirming the diagnosis of therapy‐related AML (t‐AML). No residual CLL was present. Together with previous reports of secondary cancers after fludarabine treatment and the association of monosomy 7/7q‐ with another purine analogue azathioprine, results suggest that t‐AML might develop after fludarabine therapy. Am. J. Hematol. 79:288–290, 2005. © 2005 Wiley‐Liss, Inc.